JP2002544238A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002544238A5 JP2002544238A5 JP2000617920A JP2000617920A JP2002544238A5 JP 2002544238 A5 JP2002544238 A5 JP 2002544238A5 JP 2000617920 A JP2000617920 A JP 2000617920A JP 2000617920 A JP2000617920 A JP 2000617920A JP 2002544238 A5 JP2002544238 A5 JP 2002544238A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- medicine
- patient
- treating
- erbb2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 18
- 238000000034 method Methods 0.000 description 15
- 229940079593 drug Drugs 0.000 description 13
- 206010028980 Neoplasm Diseases 0.000 description 10
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 206010019695 Hepatic neoplasm Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000037841 lung tumor Diseases 0.000 description 2
- 208000013076 thyroid tumor Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000023965 endometrium neoplasm Diseases 0.000 description 1
- 210000002165 glioblast Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000013718 rectal benign neoplasm Diseases 0.000 description 1
- 208000017572 squamous cell neoplasm Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13408599P | 1999-05-14 | 1999-05-14 | |
| US60/134,085 | 1999-05-14 | ||
| PCT/US2000/012552 WO2000069460A1 (en) | 1999-05-14 | 2000-05-09 | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011156126A Division JP2011246480A (ja) | 1999-05-14 | 2011-07-14 | 抗−ＥｒｂＢ２抗体による治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002544238A JP2002544238A (ja) | 2002-12-24 |
| JP2002544238A5 true JP2002544238A5 (https=) | 2007-06-21 |
| JP5623681B2 JP5623681B2 (ja) | 2014-11-12 |
Family
ID=22461712
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000617920A Expired - Lifetime JP5623681B2 (ja) | 1999-05-14 | 2000-05-09 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2011156126A Withdrawn JP2011246480A (ja) | 1999-05-14 | 2011-07-14 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2014151231A Pending JP2015007056A (ja) | 1999-05-14 | 2014-07-24 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2016000187A Pending JP2016128428A (ja) | 1999-05-14 | 2016-01-04 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2017074178A Withdrawn JP2017160210A (ja) | 1999-05-14 | 2017-04-04 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2018207867A Pending JP2019055961A (ja) | 1999-05-14 | 2018-11-05 | 抗−ＥｒｂＢ２抗体による治療 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011156126A Withdrawn JP2011246480A (ja) | 1999-05-14 | 2011-07-14 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2014151231A Pending JP2015007056A (ja) | 1999-05-14 | 2014-07-24 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2016000187A Pending JP2016128428A (ja) | 1999-05-14 | 2016-01-04 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2017074178A Withdrawn JP2017160210A (ja) | 1999-05-14 | 2017-04-04 | 抗−ＥｒｂＢ２抗体による治療 |
| JP2018207867A Pending JP2019055961A (ja) | 1999-05-14 | 2018-11-05 | 抗−ＥｒｂＢ２抗体による治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20030170235A1 (https=) |
| EP (1) | EP1187632B1 (https=) |
| JP (6) | JP5623681B2 (https=) |
| AT (1) | ATE415979T1 (https=) |
| AU (1) | AU782325B2 (https=) |
| CA (1) | CA2374085C (https=) |
| CY (1) | CY1108765T1 (https=) |
| DE (1) | DE60040981D1 (https=) |
| DK (1) | DK1187632T3 (https=) |
| ES (1) | ES2320311T3 (https=) |
| PT (1) | PT1187632E (https=) |
| SI (1) | SI1187632T1 (https=) |
| WO (1) | WO2000069460A1 (https=) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US7041292B1 (en) | 1999-06-25 | 2006-05-09 | Genentech, Inc. | Treating prostate cancer with anti-ErbB2 antibodies |
| CA2376596C (en) * | 1999-06-25 | 2009-10-06 | Genentech, Inc. | Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies |
| US20030086924A1 (en) * | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) * | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6949245B1 (en) | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| EP1191944A2 (en) * | 1999-06-25 | 2002-04-03 | Genentech, Inc. | METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| GB9917012D0 (en) * | 1999-07-20 | 1999-09-22 | Pharmacia & Upjohn Spa | Combined preparations comprising antitumor agents |
| US7060284B1 (en) * | 1999-08-03 | 2006-06-13 | The Ohio State University | Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein |
| AU775373B2 (en) | 1999-10-01 | 2004-07-29 | Immunogen, Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| KR20130056201A (ko) | 2000-05-19 | 2013-05-29 | 제넨테크, 인크. | ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석 |
| AT413487B (de) * | 2002-08-12 | 2006-03-15 | Igeneon Krebs Immuntherapie | Verwendung von antikörpern gegen ein tumor-assoziiertes antigen |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| CN102558352A (zh) * | 2003-06-27 | 2012-07-11 | 艾默根佛蒙特有限公司 | 针对表皮生长因子受体的缺失突变体的抗体及其使用 |
| KR20140032004A (ko) | 2004-07-22 | 2014-03-13 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| JP2008523073A (ja) * | 2004-12-07 | 2008-07-03 | ジェネンテック・インコーポレーテッド | Ｈｅｒ阻害剤を用いた治療のための患者の選択 |
| CA2592177A1 (en) | 2005-01-21 | 2006-07-27 | Genentech, Inc. | Fixed dosing of her antibodies |
| EP1850874B1 (en) | 2005-02-23 | 2013-10-16 | Genentech, Inc. | Extending time to disease progression or survival in ovarian cancer patients using pertuzumab |
| CA2606081C (en) * | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| JP2006316040A (ja) * | 2005-05-13 | 2006-11-24 | Genentech Inc | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| EP1912680B1 (en) * | 2005-06-15 | 2014-11-26 | The Ohio State University Research Foundation | Her-2 peptides |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7498142B2 (en) * | 2006-01-31 | 2009-03-03 | Yeda Research And Development Co., Ltd. | Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies |
| TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| DK2056874T3 (da) | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
| MX2009008981A (es) | 2007-03-02 | 2009-09-02 | Genentech Inc | Prediccion de respuesta a un inhibidor her. |
| US20090304590A1 (en) * | 2007-05-29 | 2009-12-10 | Wyeth | Therapeutic compositions and methods |
| US20090258005A1 (en) * | 2007-05-29 | 2009-10-15 | Trubion Pharmaceuticals Inc. | Therapeutic compositions and methods |
| US9551033B2 (en) | 2007-06-08 | 2017-01-24 | Genentech, Inc. | Gene expression markers of tumor resistance to HER2 inhibitor treatment |
| EP2171090B1 (en) | 2007-06-08 | 2013-04-03 | Genentech, Inc. | Gene expression markers of tumor resistance to her2 inhibitor treatment |
| CA2711843C (en) | 2007-12-20 | 2018-11-13 | Laboratory Corporation Of America Holdings | Her-2 diagnostic methods |
| EP2085466A1 (en) * | 2008-01-29 | 2009-08-05 | AEterna Zentaris GmbH | Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| CN107325182A (zh) | 2008-04-02 | 2017-11-07 | 宏观基因有限公司 | HER2/neu‑特异性抗体和其使用方法 |
| ES2342646B1 (es) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| US8883149B2 (en) * | 2008-09-15 | 2014-11-11 | Yeda Research And Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| MX2011003381A (es) * | 2008-09-30 | 2011-04-21 | Abbott Lab | Metodo mejorado para despliegue de arn. |
| AU2009308707A1 (en) | 2008-10-31 | 2010-05-06 | Biogen Idec Ma Inc. | LIGHT targeting molecules and uses thereof |
| US8470542B2 (en) | 2008-12-01 | 2013-06-25 | Laboratory Corporation Of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| EP3115063A3 (en) | 2008-12-03 | 2017-04-19 | The John Hopkins University | Galectin-3 and annexin-a2 as immunological target |
| SG172983A1 (en) | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
| US20100234283A1 (en) | 2009-02-04 | 2010-09-16 | The Ohio State University Research Foundation | Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use |
| CN104447995A (zh) | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| EP2435071A1 (en) | 2009-05-29 | 2012-04-04 | F. Hoffmann-La Roche AG | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
| DK2536748T3 (da) | 2010-02-18 | 2014-10-13 | Genentech Inc | Neuregulin-antagonister og anvendelse deraf ved behandling af kræft |
| WO2011146568A1 (en) | 2010-05-19 | 2011-11-24 | Genentech, Inc. | Predicting response to a her inhibitor |
| JP6082344B2 (ja) | 2010-05-27 | 2017-02-15 | ゲンマブ エー／エス | Ｈｅｒ２エピトープに対するモノクローナル抗体 |
| CN114805583A (zh) | 2010-05-27 | 2022-07-29 | 根马布股份公司 | 针对her2的单克隆抗体 |
| US20130245233A1 (en) | 2010-11-24 | 2013-09-19 | Ming Lei | Multispecific Molecules |
| JP5766296B2 (ja) | 2010-12-23 | 2015-08-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用 |
| CA2832389A1 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| US9040047B2 (en) | 2011-05-16 | 2015-05-26 | Yeda Research And Development Co. Ltd. | Combinations of anti ErbB antibodies for the treatment of cancer |
| US20140363438A1 (en) | 2011-08-17 | 2014-12-11 | Genentech, Inc. | Neuregulin antibodies and uses thereof |
| WO2013055874A2 (en) | 2011-10-14 | 2013-04-18 | Genentech, Inc. | Uses for and article of manufacture including her2 dimerization inhibitor pertuzumab |
| WO2013063229A1 (en) | 2011-10-25 | 2013-05-02 | The Regents Of The University Of Michigan | Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells |
| RU2014126098A (ru) | 2011-11-30 | 2016-01-27 | Дженентек, Инк. | МУТАЦИИ ErbB3 ПРИ РАКЕ |
| US9376715B2 (en) | 2011-12-09 | 2016-06-28 | Roche Molecular Systems, Inc | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene |
| RU2014136886A (ru) | 2012-03-27 | 2016-05-20 | Дженентек, Инк. | Диагностика и виды лечения, связанные с ингибиторами her3 |
| KR102291355B1 (ko) | 2012-11-30 | 2021-08-19 | 에프. 호프만-라 로슈 아게 | Pd-l1 억제제 공동치료를 필요로 하는 환자의 식별방법 |
| RU2019115089A (ru) | 2013-04-16 | 2019-06-11 | Дженентек, Инк. | Варианты пертузумаба и их аналитическая характеристика |
| JP2017513901A (ja) | 2014-04-25 | 2017-06-01 | ジェネンテック， インコーポレイテッド | トラスツズマブ−ｍｃｃ−ｄｍ１及びペルツズマブにより早期の乳癌を処置する方法 |
| US11406715B2 (en) | 2015-05-30 | 2022-08-09 | Genentech, Inc. | Methods of treating HER2-positive metastatic breast cancer |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| WO2017194554A1 (en) | 2016-05-10 | 2017-11-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Combinations therapies for the treatment of cancer |
| AU2017355432A1 (en) | 2016-11-04 | 2019-05-16 | F. Hoffmann-La Roche Ag | Treatment of HER2-positive breast cancer |
| AU2017387909A1 (en) | 2016-12-28 | 2019-06-27 | Genentech, Inc. | Treatment of advanced HER2 expressing cancer |
| SG11201905622VA (en) | 2017-01-17 | 2019-08-27 | Genentech Inc | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| EP3615695A1 (en) | 2017-04-24 | 2020-03-04 | Genentech, Inc. | Erbb2/her2 mutations in the transmebrane or juxtamembrane domain |
| AU2020456731A1 (en) | 2020-06-29 | 2023-01-05 | F. Hoffmann-La Roche Ag | Pertuzumab plus trastuzumab fixed dose combination |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1989006692A1 (en) * | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| US5720937A (en) * | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| US5578482A (en) * | 1990-05-25 | 1996-11-26 | Georgetown University | Ligand growth factors that bind to the erbB-2 receptor protein and induce cellular responses |
| EP1400536A1 (en) * | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| BR9806793A (pt) * | 1997-01-22 | 2000-05-16 | Univ Texas | Processos e composições de fator tissular para coagulação e tratamento de tumores. |
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
-
2000
- 2000-05-09 JP JP2000617920A patent/JP5623681B2/ja not_active Expired - Lifetime
- 2000-05-09 DE DE60040981T patent/DE60040981D1/de not_active Expired - Lifetime
- 2000-05-09 CA CA2374085A patent/CA2374085C/en not_active Expired - Lifetime
- 2000-05-09 EP EP00928916A patent/EP1187632B1/en not_active Revoked
- 2000-05-09 DK DK00928916T patent/DK1187632T3/da active
- 2000-05-09 PT PT00928916T patent/PT1187632E/pt unknown
- 2000-05-09 AU AU47080/00A patent/AU782325B2/en not_active Expired
- 2000-05-09 ES ES00928916T patent/ES2320311T3/es not_active Expired - Lifetime
- 2000-05-09 AT AT00928916T patent/ATE415979T1/de active
- 2000-05-09 SI SI200031018T patent/SI1187632T1/sl unknown
- 2000-05-09 WO PCT/US2000/012552 patent/WO2000069460A1/en not_active Ceased
-
2003
- 2003-05-05 US US10/429,519 patent/US20030170235A1/en not_active Abandoned
-
2007
- 2007-09-06 US US11/851,298 patent/US20080050373A1/en not_active Abandoned
-
2009
- 2009-02-12 CY CY20091100158T patent/CY1108765T1/el unknown
-
2011
- 2011-07-14 JP JP2011156126A patent/JP2011246480A/ja not_active Withdrawn
-
2013
- 2013-12-26 US US14/141,190 patent/US20140322202A1/en not_active Abandoned
-
2014
- 2014-07-24 JP JP2014151231A patent/JP2015007056A/ja active Pending
-
2016
- 2016-01-04 JP JP2016000187A patent/JP2016128428A/ja active Pending
-
2017
- 2017-04-04 JP JP2017074178A patent/JP2017160210A/ja not_active Withdrawn
-
2018
- 2018-01-26 US US15/880,851 patent/US20180162951A1/en not_active Abandoned
- 2018-11-05 JP JP2018207867A patent/JP2019055961A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002544238A5 (https=) | ||
| RU2430739C2 (ru) | Способ лечения рака у человека (варианты), применяемая в способе форма (варианты) и применение антитела (варианты) | |
| MXPA02010059A (es) | Metodo para administrar un anticuerpo. | |
| JP2020536109A5 (https=) | ||
| JP2020510039A5 (https=) | ||
| JP2009505676A5 (https=) | ||
| RU2008128244A (ru) | Способы идентификации опухолей, восприимчивых к лечению антителами против erbb2 | |
| MY151449A (en) | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 | |
| JP2002535285A5 (https=) | ||
| JP2003503361A5 (https=) | ||
| ATE307608T1 (de) | Kombination von doctaxel und rhumab her2 zür krebsbehandlung | |
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| EP1410804A4 (en) | CANCER VACCINE WITH CANCER ANTIGENS BASED ON TUMOR SUPPRESSOR GEN WT1 PRODUCT AND CATIONIC LIPOSOME | |
| JP2006506441A5 (https=) | ||
| HUP0401605A2 (hu) | Szembetegségek kezelésére szolgáló integrin gátlók | |
| WO2004002445A3 (en) | Novel floating dosage form | |
| JP2016216479A (ja) | 組み合わせ医薬組成物及び呼吸器の疾患又は状態に関連する疾患及び状態を治療する方法 | |
| MXPA01008612A (es) | Epitopos o mimotopos derivados de los dominos c-epsilon-3 o c-epsilon-4 de ige, antagonistas de los mismos y sus usos terapeuticos. | |
| IL182352A (en) | Use of et-743 in the preparation of a medicament for treating cancer and medical kits containing et-743 | |
| EP1758998A4 (en) | OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF IN THE TREATMENT OF FIBROUS CONDITIONS AND OTHER DISEASES | |
| CN116712539A (zh) | 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途 | |
| AR030019A1 (es) | Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m | |
| PL1643999T3 (pl) | Pirydoksamina do zastosowania w leczeniu nefropatii cukrzycowej w cukrzycy typu II | |
| Swapnil et al. | Targeted Drug Delivery: A Backbone for Cancer Therapy | |
| JPWO2019154986A5 (https=) |